Healthcare, Pharma & Life Sciences

BCG: Women's Longevity Care Gap Worth $350 Billion Globally

Image
BCG: Women's Longevity Care Gap Worth $350 Billion Globally

Boston – September 22, 2026 -- Women in perimenopause or menopause represent an estimated $350 billion in unmet demand within the global longevity market, according to a new Boston Consulting Group (BCG) study covering roughly 1 billion women worldwide already spending on longevity products and services.

Women outspend every other demographic on longevity but remain equally dissatisfied

The BCG report, titled "The $350 Billion Longevity Mismatch in Women's Health," surveyed 10,608 people across 12 countries for the St. Moritz Longevity Forum. Women in perimenopause or menopause spend a median $84 a month on longevity interventions, compared with $68 for other women and $73 for men. Roughly a third of these women said they would spend $108 a month if a product or service delivered visible results.

Bestzyme Opens First Automated Sweet Protein Plant in Jinan

Image
Bestzyme Opens First Automated Sweet Protein Plant in Jinan

Jinan – September 22, 2026 -- Bestzyme, a synthetic biology unit of GenScript Biotech, has completed what it calls the world's first dedicated, automated smart production line for sweet proteins at its Jinan facility, integrating R&D, mass production and application for the ingredient category for the first time globally.

Jinan facility delivers 100 tons of annual capacity equal to 300,000 tons of sucrose sweetness

The 5,000-square-meter plant runs a fully automated fermentation-purification-freeze-drying process for Bestzyme's flagship Mellia® Brazzein sweet protein. Once operational, the line will produce over 100 tons annually, a volume the company says matches the sweetness output of 300,000 tons of sucrose. Bestzyme expects capacity to potentially double within two years.

Tethis Acquires See.d Platform from MACS, Taps Everex to Scale Production

Image
Tethis Acquires See.d Platform from MACS, Taps Everex to Scale Production

Milan – September 22, 2026 -- Tethis S.p.A. has completed the acquisition of the See.d software and engineering business unit from MACS S.r.l., gaining full control over intellectual property and engineering know-how behind its liquid biopsy platform. Alongside the transfer, Tethis signed a long-term manufacturing and supply agreement with Everex S.r.l., an Italian in-vitro diagnostic instrumentation maker, to handle production and future scale-up of the system.

Tethis consolidates full ownership of its liquid biopsy pre-analytical platform

See.d is the cornerstone of Tethis' liquid biopsy workflow, developed jointly with MACS to standardize pre-analytical blood processing. From a single blood sample, the platform generates plasma for cfDNA analysis and cytology slides preserving nucleated cells for downstream characterization, automating plasma separation, red blood cell lysis, and deposition onto Tethis' proprietary SmartBioSurface slides.

Hackensack Meridian CEO Robert Garrett to Retire June 2027

Image
Hackensack Meridian CEO Robert Garrett to Retire June 2027

Iselin, N.J. – September 22, 2026 -- Hackensack Meridian Health's Board of Trustees announced that CEO Robert C. Garrett will retire effective September 22, 2026, ending a tenure that built New Jersey's largest health network from the ground up. A national search for his successor is now underway, with the Board targeting a decision by the end of the first quarter of 2027.

Network expanded to 18 hospitals and 41,000 employees over ten years

Since HMH's creation a decade ago, the system has grown to 18 hospitals, 41,000 team members and more than 500 patient care locations across New Jersey — nearly triple its size at launch. Under Garrett, the network also opened the Hackensack Meridian School of Medicine, the state's first new private medical school in decades, alongside a new discovery research center.

Merry Life Advances TML-6 Into 210-Patient Global Alzheimer's Phase 2

Image
Merry Life Advances TML-6 Into 210-Patient Global Alzheimer's Phase 2

Taipei – September 22, 2026 -- Merry Life Biomedical has advanced TML-6, a Taiwan-developed oral therapy for early Alzheimer's disease, into a global Phase 2 trial spanning 20 clinical sites across Taiwan, Sweden, and the United States, targeting approximately 210 participants.

Twenty sites across three countries anchor the trial's design

The study includes nine medical centers in Taiwan, seven sites in Sweden, and four centers in the United States, with Taiwan forming the largest single group of participating sites. The randomized, double-blind, placebo-controlled trial will assign patients to TML-6 100 mg, TML-6 200 mg, or placebo, administered once daily for 52 weeks.

Akeso's Ivonescimab Wins ESMO Late-Breaking Slot for Biliary Cancer Data

Hong Kong – September 22, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Phase III biliary tract cancer trial secures Presidential Symposium slot

Overall survival results from the Phase III HARMONi-GI1 trial, comparing ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer, will be delivered as a late-breaking oral presentation (LBA8) on October 25 at 16:30-18:15 in Madrid. The presentation will be given by Jian Zhou of Shanghai during Presidential Symposium II.

Pharma Logistics Market to Nearly Double to $194B by 2034

Image
Pharma Logistics Market to Nearly Double to $194B by 2034

Pune, India – September 22, 2026 -- The global pharmaceutical logistics market is set to nearly double from approximately $100.0 billion in 2025 to $194.0 billion by 2034, expanding at a 7.7% compound annual growth rate, according to a new report from Maximize Market Research.

Cold-chain demand for biologics and vaccines drives infrastructure investment

Growth is being fueled by rising volumes of biologics, vaccines, specialty medicines and clinical trial materials that require validated temperature control. Logistics providers are investing in refrigerated transportation, specialized cold storage warehousing and real-time temperature monitoring to protect product integrity across international drug distribution networks.

Lilly Breaks Ground on $6.5B Houston API Plant for Foundayo

Image
Lilly Breaks Ground on $6.5B Houston API Plant for Foundayo

Houston – – September 22, 2026 -- Eli Lilly and Company (NYSE: LLY) has broken ground on a $6.5 billion manufacturing site in Houston, Texas, that will produce active pharmaceutical ingredients for Foundayo (orforglipron), the company's first synthetic oral GLP-1 medicine for weight management.

Houston site becomes Lilly's fifth domestic API facility since 2020

The plant is one of ten U.S. manufacturing sites Lilly has announced since 2020 and the fifth dedicated to producing active pharmaceutical ingredients domestically. The investment falls under Lilly's broader $50 billion initiative to reshore medicine production in the United States and export American-made drugs globally.

PTC Therapeutics Closes ST-920 Fabry Gene Therapy Acquisition

Warren, N.J. – September 22, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc.

PTC targets Q4 2026 completion of rolling BLA submission for accelerated approval

The company confirmed that a rolling Biologics License Application submission to the FDA seeking accelerated approval of ST-920, also known as isaralgagene civaparvovec, is expected to be completed in the fourth quarter of 2026.

BD Names Ex-Lenovo Executive Art Hu as Chief Digital Officer

Image
BD Names Ex-Lenovo Executive Art Hu as Chief Digital Officer

Franklin Lakes, N.J. – September 22, 2026 -- BD (Becton, Dickinson and Company), listed on the NYSE under BDX, has appointed Arthur (Art) Hu as executive vice president and chief information and digital officer, effective September 30.

Hu Joins BD From Lenovo's Solutions and Services Group

Hu departs Lenovo Group, where he served as senior vice president, global chief information officer and chief technology and delivery officer for the Solutions and Services Group. He brings more than 25 years of experience in global technology, digital and business transformation. Prior to Lenovo, Hu spent over a decade at McKinsey & Company advising organizations on technology, operations and strategy.

Appointment Follows Retirement of Longtime BD Technology Chief

Hu succeeds Denise Russell Fleming, who will retire from BD at the end of 2026.